Phaseline

Companies › Hangzhou Zhongmei Huadong Pharmaceutical

Hangzhou Zhongmei Huadong Pharmaceutical: clinical trials, targets and expected readouts

12 active drug programs in 25 registered trials: 15 Phase 1, 5 Phase 3, 3 Phase 2, 2 Phase 4; Oncology, Metabolic and endocrine, Gastroenterology, Other; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ganagliflozin
SGLT-2 inhibitor
SLC5A2Phase 4T2DM (Type 2 Diabetes Mellitus)Dec 2027
liraglutide
Glucagon-like peptide 1 receptor agonist
GLP1RPhase 4T2DM (Type 2 Diabetes Mellitus)Dec 2027
HDM1005 injection
GLP-1 receptor agonist
GLP1RPhase 3Obesity & Overweight; Type 2 Diabetes; Obesity; Overweight and/or ObesityNov 2026
HDM1002–Phase 3Type 2 Diabetes; Overweight Subject; Hepatic Impairment; Healthy Adult SubjectFeb 2027
HDM1702
GLP-1 receptor agonist
–Phase 3Obesity Control–
HDM2017–Phase 1Solid Tumors; CRC, Colorectal CancerDec 2026
HDP-101–Phase 1Multiple Myeloma and Other Plasma Cell NeoplasmsDec 2026
HDM2020
FGFR2b-targeted antibody-drug conjugate
FGFR2Phase 1Squamous Non-small Cell Lung Cancer(NSCLC); Solid TumorJan 2027
HDM2006–Phase 1Advanced Solid TumorsMar 2027
HDM2024
Antibody-drug conjugate targeting EGFR and HER3
EGFR, HER3Phase 1Advanced Solid TumorsApr 2027
HDM2005
PROTAC-mediated MDM2 degradation
–Phase 1Advanced Solid Tumors; Diffuse Large B Cell Lymphoma (DLBCL)Jul 2027
HDM2012–Phase 1Advanced Solid TumorsOct 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06886126HDM1005 injectionPhase 2ObesityMetabolic and endocrineSep 2025
NCT07331389HDM1002Phase 1Overweight SubjectMetabolic and endocrineJan 2026
NCT06985615HDM1002Phase 1Hepatic ImpairmentGastroenterologyJan 2026
NCT07109700HDM1005 injectionPhase 2Type 2 DiabetesMetabolic and endocrineJan 2026
NCT07036172HDM1702Phase 3Obesity ControlMetabolic and endocrineApr 2026
NCT07594847HDM1002Phase 1Healthy Adult SubjectOtherSep 2026
NCT07828197HDM1005 injectionPhase 1Overweight and/or ObesityMetabolic and endocrineNov 2026
NCT07279194HDM1005 injectionPhase 3Obesity & OverweightMetabolic and endocrineDec 2026
NCT07529782HDP-101Phase 1Multiple Myeloma and Other Plasma Cell NeoplasmsOncologyDec 2026
NCT07274085HDM2017Phase 1Solid TumorsOncologyDec 2026
NCT07638891HDM2020Phase 1Squamous Non-small Cell Lung Cancer(NSCLC)OncologyJan 2027
NCT07193459HDM1002Phase 3Type 2 DiabetesMetabolic and endocrineFeb 2027
NCT07521631HDM1005 injectionPhase 2ObesityMetabolic and endocrineFeb 2027
NCT07082114HDM1002Phase 3Type 2 DiabetesMetabolic and endocrineFeb 2027
NCT07377591HDM2006Phase 1Advanced Solid TumorsOncologyMar 2027
NCT07539285HDM2024Phase 1Advanced Solid TumorsOncologyApr 2027
NCT07098052HDM2020Phase 1Solid TumorOncologyMay 2027
NCT07004296HDM2005Phase 1Advanced Solid TumorsOncologyJul 2027
NCT07394114HDM1005 injectionPhase 3Type 2 DiabetesMetabolic and endocrineAug 2027
NCT07100249HDM2012Phase 1Advanced Solid TumorsOncologyOct 2027
NCT07124936HDM2005Phase 1Diffuse Large B Cell Lymphoma (DLBCL)OncologyOct 2027
NCT07244003ganagliflozinPhase 4T2DM (Type 2 Diabetes Mellitus)Metabolic and endocrineDec 2027
NCT07244003liraglutidePhase 4T2DM (Type 2 Diabetes Mellitus)Metabolic and endocrineDec 2027
NCT06615193HDM2005Phase 1Advanced Solid TumorsOncologyFeb 2028
NCT07805551HDM2017Phase 1CRC, Colorectal CancerOncologyAug 2030

Targets

GLP1R (2) FGFR2 (1) EGFR (1) HER3 (1) SLC5A2 (1)

Companies with the same targets

AstraZeneca Eli Lilly Novo Nordisk Shanghai Henlius Biotech Roche Chia Tai Tianqing Pharmaceutical Group Hangzhou Sciwind Biosciences Johnson & Johnson (Janssen) Allist Pharmaceuticals Dizal Pharmaceuticals

Companies built like this

Hanmi Pharmaceutical Company Changchun GeneScience Pharmaceutical Shanghai JMT-Bio Sichuan Baili Pharmaceutical Dong-A ST

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.